Pharsight

Ortho Evra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5972377 JANSSEN PHARMS Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
Jun, 2015

(8 years ago)

US5876746 JANSSEN PHARMS Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
Nov, 2015

(8 years ago)

Ortho Evra is owned by Janssen Pharms.

Ortho Evra contains Ethinyl Estradiol; Norelgestromin.

Ortho Evra has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Ortho Evra are:

  • US5972377
  • US5876746

Ortho Evra was authorised for market use on 20 November, 2001.

Ortho Evra is available in film, extended release;transdermal dosage forms.

Ortho Evra can be used as prevention of ovulation in a woman.

The generics of Ortho Evra are possible to be released after 20 November, 2015.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ETHINYL ESTRADIOL; NORELGESTROMIN ingredient

Market Authorisation Date: 20 November, 2001

Treatment: Prevention of ovulation in a woman

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of ORTHO EVRA before it's drug patent expiration?
More Information on Dosage

ORTHO EVRA family patents

Family Patents